Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

Inclusion Criteria: * Male or female outpatient, 18 years or older; * The patient has an established diagnosis of epilepsy and has experienced at least one partial-onset seizure, with or without secondary generalization, within four weeks prior to initiation of adjunctive ESL; * The patient is not sufficiently controlled on a current antiepileptic monotherapy and, in the neurologist clinical judgment, it is in the patient's best interest to be prescribed with adjunctive ESL; * The neurologist's decision to prescribe ESL has been made before and independently of his/her decision to include the patient in this study; * The patient's treatment is in accordance with the SPC of ESL; * Written informed consent from the patient (or legally acceptable representative, if the subject is unable to provide informed consent). Exclusion Criteria: * Known hypersensitivity to the active substance, carboxamide derivatives (e.g. oxcarbazepine or carbamazepine) or to any of its excipients; * Patient with 2nd or 3rd degree atrioventricular block; * Patient treated with an experimental drug within four weeks prior to the introduction of ESL; * Female patient who is pregnant, lactating, or who is planning to become pregnant during the study period; * Patient starting ESL outside the approved SPC at enrolment.